Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 11/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GOT1 | P17174 | 1/20 | 0.47 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803837 | 0.94 | STING1 (0.77) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL28991332 | 0.86 | STING1 (0.72) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL30386673 | 0.86 | STING1 (0.72) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL30885411 | 0.85 | STING1 (0.70) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL23167133 | 0.85 | STING1 (0.70) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL30196046 | 0.83 | STING1 (0.65) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL23208067 | 0.83 | STING1 (0.65) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL23208061 | 0.82 | STING1 (0.64) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL23207905 | 0.82 | STING1 (0.63) | STING1EPHX2MEN1KMT2AMAPT | |
| SCHEMBL30196153 | 0.82 | STING1 (0.63) | STING1EPHX2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | STING1 1/4885EPHX2 2928/4885MEN1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.